**Demo Report**

*Report Issued* 03/30/2020 11:59  
*Last Report Issued* 05/13/2019 08:05

**Patient Name** 1440SP-POS  
**Patient ID** 1440SP-POS  
**Chain** 18001949  
**Age** Not Given  
**DOB** Not Given  
**Gender** Not Given  
**Workorder** 18001949  
**Received** 11/21/2018 10:33

---

**Sample ID** 18001949-001  
**Matrix** Serum or Plasma  
**Patient Name** 1440SP-POS  
**Patient ID** 1440SP-POS  
**Container Type** Clear vial  
**Collect Dt/Tm** Not Given  
**Source** Not Given  
**Approx Vol/Weight** Not Given  

**Receipt Notes** None Entered

---

**Analysis and Comments**

<table>
<thead>
<tr>
<th>Result</th>
<th>Units</th>
<th>Reporting Limit</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1440SP Dapsone and Metabolite, Serum/Plasma</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dapsone</td>
<td>50</td>
<td>mcg/mL</td>
<td>0.10</td>
</tr>
</tbody>
</table>
| Synonym(s): Aczone®  
Steady-state plasma concentrations from patients on 200 mg daily antileprotic therapy: 0.1 - 7.0 mcg/mL  
(mean = 2.3 mcg/mL). | | | |
| Monoacetyldapsone | 50 | mcg/mL | 0.10 |
| Synonym(s): Dapsone Metabolite  
Monoacetyldapsone is an active metabolite of dapsone  
with antibacterial activity. | | | |
| Monoacetyldapsone to Dapsone Ratio | 1.0 | | |
| Monoacetyldapsone to Dapsone Ratio (for acetylation phenotyping purposes):  
Slow acetylator: <0.35  
Rapid acetylator: >0.35 | | | |

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.